Methods for preventing or reducing colon carcinogenesis
The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising a chemopreventive agent disclosed herein.
1. A method of inhibiting colon carcinogenesis comprising: administering to a patient at risk of colorectal cancer a pharmaceutical preparation comprising an agent represented by:
or pharmaceutically acceptable salts or stereoisomers thereof.
2. The method of claim 1 , wherein the patient is human.
3. The method of claim 2 , wherein the patient does not have detectable colorectal cancer.
4. The method of claim 1 , wherein upon or before administration, spontaneous mutation frequency of colon carcinoma cells are present in the patient.
5. The method of claim 1 , wherein the patient has Crohn's disease, inflammatory bowel disease, or ulcerative colitis.
6. A method for delaying clinical manifestation of colon adenocarcinoma in a patient at risk of colon cancer, comprising administering to the patient an effective amount of a compound of represented by:
or pharmaceutically acceptable salts or stereoisomers thereof.
7. The method of claim 6 , wherein the delay is at least 1 year as compared to a patient who is not administered the compound.
8. The method of claim 6 , wherein the patient has at least about a 30% reduction of the mutation rate of colon carcinoma cells present in the patient.
9. The method of claim 6 , wherein the patient is at higher risk of having the adenocarcinoma as compared to a general population.
10. The method of claim 9 , wherein the patient has a genetically based risk.
11. The method of claim 6 , wherein the compound is administered systemically.
12. The method of claim 6 , wherein the compound is administered orally.
13. A composition suitable for systemic administration to a patient having a colorectal tumor, said composition comprising a compound represented by:
or pharmaceutically acceptable salts or stereoisomers thereof; and a pharmaceutically acceptable excipient; wherein the compound is present in an amount effective to inhibit the growth of the tumor when administered systemically.
14. The composition of claim 13 , wherein the inhibition of growth of said tumor is measured as a delay in tumor doubling time.
15. The composition of claim 14 , wherein the tumor doubling time is extended by a factor of two.
16. The composition of claim 15 , wherein the inhibition of growth of said tumor is measured by a reduction in the volume of said tumor.
17. The composition of claim 16 , wherein the volume of the tumor is reduced by at least 30%.